GLOB:NYSEGlobant S.A. Analysis
Data as of 2026-04-06 - not real-time
$47.85
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Globant trades around $47.85, comfortably above its 20‑day SMA of 45.96 but below the 50‑day SMA of 51.86 and far under the 200‑day SMA of 65.05, signalling a short‑term bearish bias. The RSI sits near the midpoint at 51, while the MACD histogram is positive (0.73) indicating a nascent bullish momentum despite the overall trend being labeled bearish. Volatility is elevated at 54.7% over the past 30 days and beta exceeds 1.4, underscoring heightened price swings and market sensitivity. A DCF‑derived fair value of $83.26 implies roughly 51% upside, and the stock’s trailing P/E of 20.9 is well below the industry average of 33.5, while the forward P/E compresses to 7.2, reflecting strong earnings expectations. Fundamental metrics show modest revenue contraction (-4.7%) but solid profitability with a gross margin of 35%, operating margin of 19%, and free cash flow generation topping $291 M. The latest earnings release highlighted record free cash flow and accelerating adoption of AI‑native Pods, a strategic growth engine. Analyst consensus remains a Buy with 22 contributors, and the Fear & Greed Index sits at 78.8 (Extreme Greed), suggesting optimistic market sentiment.
Given the disconnect between a compelling long‑term valuation narrative and a fragile short‑term technical setup, investors should weigh the upside potential against the near‑term price weakness, elevated volatility, and decreasing volume trend. The absence of a dividend eliminates yield considerations, while the company’s global footprint introduces medium‑to‑high geographic exposure. Overall, the stock appears undervalued with strong growth catalysts, but traders should remain cautious of the bearish technical backdrop.
Given the disconnect between a compelling long‑term valuation narrative and a fragile short‑term technical setup, investors should weigh the upside potential against the near‑term price weakness, elevated volatility, and decreasing volume trend. The absence of a dividend eliminates yield considerations, while the company’s global footprint introduces medium‑to‑high geographic exposure. Overall, the stock appears undervalued with strong growth catalysts, but traders should remain cautious of the bearish technical backdrop.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below 50‑day SMA and near resistance at $53.56
- Decreasing volume trend and high 30‑day volatility
- Support level at $42 providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggests >50% upside
- Forward P/E of 7.2 indicating strong earnings growth
- Record free cash flow and rollout of AI‑native Pods
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strategic positioning in AI‑driven digital transformation
- Undervalued relative to industry peers and robust cash generation
- Sustained analyst buy consensus and favorable market sentiment
Key Metrics & Analysis
Financial Health
Revenue Growth-4.70%
Profit Margin4.19%
P/E Ratio20.9
ROE4.96%
ROA4.74%
Debt/Equity24.23
P/B Ratio1.0
Op. Cash Flow$301.2M
Free Cash Flow$291.9M
Industry P/E33.5
Technical Analysis
TrendBearish
RSI51.4
Support$42.00
Resistance$53.56
MA 20$45.96
MA 50$51.86
MA 200$65.05
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8
Valuation
Fair Value$83.26
Target Price$72.45
Upside/Downside51.42%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.40
Volatility54.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.